142 Einträge | 1, 2, 3, 4, 5, 6, 7, 8 › » |
Seite 1 / 8
![]() |
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. |
Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Chia SKL, Mansi J, Barrios CH, Gnant M, Tomašević Z, Denduluri N, Šeparović R, Gokmen E, Bashford A, Ruiz Borrego M, Kim SB, Jakobsen EH, Ciceniene A, Inoue K, Overkamp F, Heijns JB, Armstrong AC, Link JS, Joy AA, Bryce R, Wong A, Moran S, Yao B, Xu F, Auerbach A, Buyse M, Chan A |
The Lancet. Oncology. 2017 Nov 13. pii: S1470-2045(17)30717-9. doi: 10.1016/S1470-2045(17)30717-9 |
PMID: 29146401 |
Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial. |
Chan A, Moy B, Mansi J, Ejlertsen B, Holmes FA, Chia S, Iwata H, Gnant M, Loibl S, Barrios CH, Somali I, Smichkoska S, Martinez N, Alonso MG, Link JS, Mayer IA, Cold S, Murillo SM, Senecal F, Inoue K, Ruiz-Borrego M, Hui R, Denduluri N, Patt D, Rugo HS, Johnston SRD, Bryce R, Zhang B, Xu F, Wong A, Martin M |
Clinical breast cancer. 2020 Oct 6. pii: S1526-8209(20)30258-5. doi: 10.1016/j.clbc.2020.09.014 |
PMID: 33183970 |
Primary resistance to integrase strand-transfer inhibitors in Europe. |
Casadellà M, van Ham PM, Noguera-Julian M, van Kessel A, Pou C, Hofstra LM, Santos JR, Garcia F, Struck D, Alexiev I, Bakken Kran AM, Hoepelman AI, Kostrikis LG, Somogyi S, Liitsola K, Linka M, Nielsen C, Otelea D, Paraskevis D, Poljak M, Puchhammer-Stöckl E, Staneková D, Stanojevic M, Van Laethem K, Zidovec Lepej S, Clotet B, Boucher CA, Paredes R, Wensing AM |
The Journal of antimicrobial chemotherapy. 2015 Jul 17. pii: dkv202. doi: 10.1093/jac/dkv202 |
PMID: 26188038 |
Long-term treatment with imatinib results in profound mast cell deficiency in Ph+ chronic myeloid leukemia. |
Cerny-Reiterer S, Rabenhorst A, Stefanzl G, Herndlhofer S, Hoermann G, Müllauer L, Baumgartner S, Beham-Schmid C, Sperr WR, Mannhalter C, Sill H, Linkesch W, Arock M, Hartmann K, Valent P |
Oncotarget. 2015 Mar 5. pii: 3074. pmc: PMC4413638 |
PMID: 25605011 |
Essential versus accessory aspects of cell death: recommendations of the NCCD 2015. |
Galluzzi L, Bravo-San Pedro JM, Vitale I, Aaronson SA, Abrams JM, Adam D, Alnemri ES, Altucci L, Andrews D, Annicchiarico-Petruzzelli M, Baehrecke EH, Bazan NG, Bertrand MJ, Bianchi K, Blagosklonny MV, Blomgren K, Borner C, Bredesen DE, Brenner C, Campanella M, Candi E, Cecconi F, Chan FK, Chandel NS, Cheng EH, Chipuk JE, Cidlowski JA, Ciechanover A, Dawson TM, Dawson VL, De Laurenzi V, De Maria R, Debatin KM, Di Daniele N, Dixit VM, Dynlacht BD, El-Deiry WS, Fimia GM, Flavell RA, Fulda S, Garrido C, Gougeon ML, Green DR, Gronemeyer H, Hajnoczky G, Hardwick JM, Hengartner MO, Ichijo H, Joseph B, Jost PJ, Kaufmann T, Kepp O, Klionsky DJ, Knight RA, Kumar S, Lemasters JJ, Levine B, Linkermann A, Lipton SA, Lockshin RA, López-Otín C, Lugli E, Madeo F, Malorni W, Marine JC, Martin SJ, Martinou JC, Medema JP, Meier P, Melino S, Mizushima N, Moll U, Muñoz-Pinedo C, Nuñez G, Oberst A, Panaretakis T, Penninger JM, Peter ME, Piacentini M, Pinton P, Prehn JH, Puthalakath H, Rabinovich GA, Ravichandran KS, Rizzuto R, Rodrigues CM, Rubinsztein DC, Rudel T, Shi Y, Simon HU, Stockwell BR, Szabadkai G, Tait SW, Tang HL, Tavernarakis N, Tsujimoto Y, Vanden Berghe T, Vandenabeele P, Villunger A, Wagner EF, Walczak H, White E, Wood WG, Yuan J, Zakeri Z, Zhivotovsky B, Melino G, Kroemer G |
Cell death and differentiation. 2014 Sep 19. pii: cdd2014137. doi: 10.1038/cdd.2014.137. pmc: PMC4262782 |
PMID: 25236395 |
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. |
Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Hielscher J, Scholz M, Müller S, Link H, Niederle N, Rost A, Höffkes HG, Moehler M, Lindig RU, Modest DP, Rossius L, Kirchner T, Jung A, Stintzing S |
The Lancet. Oncology. 2014 Jul 31. pii: S1470-2045(14)70330-4. doi: 10.1016/S1470-2045(14)70330-4 |
PMID: 25088940 |
Azacitidine in CMML: matched-pair analyses of daily-life patients reveal modest effects on clinical course and survival. |
Pleyer L, Germing U, Sperr WR, Linkesch W, Burgstaller S, Stauder R, Girschikofsky M, Schreder M, Pfeilstocker M, Lang A, Sliwa T, Geissler D, Schlick K, Placher-Sorko G, Theiler G, Thaler J, Mitrovic M, Neureiter D, Valent P, Greil R |
Leukemia research. 2014 Jan 18. pii: S0145-2126(14)00023-X. doi: 10.1016/j.leukres.2014.01.006 |
PMID: 24522248 |
Rituximab, Ara-C, dexamethasone and oxaliplatin (R-ADOx) is effective for treatment of elderly patients with relapsed mantle cell lymphoma. |
Lamm W, Drach J, Kiesewetter B, Zielinksi CC, Mayerhöfer ME, Müllauer L, Raderer M |
Journal of cancer research and clinical oncology. 2013 Jul 20. doi: 10.1007/s00432-013-1475-4 |
PMID: 23873598 |
Surgical treatment of the haemophilic pseudotumour: a single centre experience. |
Panotopoulos J, Ay C, Trieb K, Funovics PT, Stockhammer V, Lang S, Holinka J, Windhager R, Pabinger I, Wanivenhaus HA |
International orthopaedics. 2012 Jul 4. doi: 10.1007/s00264-012-1593-7. pmc: PMC3460086 |
PMID: 22752668 |
Taurine chloramine induces apoptosis in human osteosarcoma cell lines. |
Pilz M, Holinka J, Vavken P, Marian B, Krepler P |
Journal of orthopaedic research : official publication of the Orthopaedic Research Society. 2012 Jun 4. doi: 10.1002/jor.22161 |
PMID: 22674504 |
Nilotinib as frontline and second-line therapy in chronic myeloid leukemia: open questions. |
Valent P, Gastl G, Geissler K, Greil R, Hantschel O, Lang A, Linkesch W, Lion T, Petzer AL, Pittermann E, Pleyer L, Thaler J, Wolf D |
Critical reviews in oncology/hematology. 2011 Sep 7. pii: S1040-8428(11)00193-4. doi: 10.1016/j.critrevonc.2011.08.002 |
PMID: 21903413 |
Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program. |
Worel N, Rosskopf K, Neumeister P, Kasparu H, Nachbaur D, Russ G, Namberger K, Witt V, Schloegl E, Zojer N, Linkesch W, Kalhs P, Greinix HT |
Transfusion. 2010 Sep 28. doi: 10.1111/j.1537-2995.2010.02896.x |
PMID: 20880037 |
Diagnostic algorithms, monitoring, prognostication, and therapy in chronic myeloid leukemia (CML): a proposal of the Austrian CML platform. |
Valent P, Lion T, Wolf D, Sillaber C, Agis H, Petzer A, Lang A, Kalhs P, Geissler D, Greil R, Linkesch W, Burgstaller S, Thaler J, Gastl G |
Wiener klinische Wochenschrift. 2008 Dec 31. doi: 10.1007/s00508-008-1100-8 |
PMID: 19116712 |
Variable frequencies of MALT lymphoma-associated genetic aberrations in MALT lymphomas of different sites. |
Streubel B, Simonitsch-Klupp I, Müllauer L, Lamprecht A, Huber D, Siebert R, Stolte M, Trautinger F, Lukas J, Püspök A, Formanek M, Assanasen T, Müller-Hermelink HK, Cerroni L, Raderer M, Chott A |
Leukemia. 2004 Sep 28. doi: 10.1038/sj.leu.2403501. pii: 2403501 |
PMID: 15356642 |
Long term follow up after allogeneic stem cell transplantation for chronic myelogenous leukemia. |
Reiter E, Greinix HT, Brugger S, Keil F, Rabitsch W, Mannhalter C, Schwarzinger I, Höcker P, Fischer G, Dieckmann K, Hinterberger W, Linkesch W, Schneider B, Lechner K, Kalhs P |
Bone marrow transplantation. 1999 Apr 7. |
PMID: 9916646 |
Granulocyte colony-stimulating factor as an adjunct to induction chemotherapy for adult acute lymphoblastic leukemia--a randomized phase-III study. |
Geissler K, Koller E, Hubmann E, Niederwieser D, Hinterberger W, Geissler D, Kyrle P, Knöbl P, Pabinger I, Thalhammer R, Schwarzinger I, Mannhalter C, Jaeger U, Heinz R, Linkesch W, Lechner K |
Blood. 1997 Aug 7. |
PMID: 9226158 |
Microangiopathy following allogeneic marrow transplantation. Association with cyclosporine and methylprednisolone for graft-versus-host disease prophylaxis. |
Kalhs P, Brugger S, Schwarzinger I, Greinix HT, Keil F, Kyrle PA, Knöbl P, Schneider B, Höcker P, Linkesch W |
Transplantation. 1996 Jan 3. |
PMID: 7491699 |
MDR1 gene expression and treatment outcome in acute myeloid leukemia. |
Pirker R, Wallner J, Geissler K, Linkesch W, Haas OA, Bettelheim P, Hopfner M, Scherrer R, Valent P, Havelec L |
Journal of the National Cancer Institute. 1991 Jun 6. |
PMID: 2023272 |
Effect of cell growth and cell differentiation on 1-beta-D-arabinofuranosylcytosine metabolism in myeloid cells. |
Chiba P, Tihan T, Eher R, Köller U, Wallner C, Göbl R, Linkesch W |
British journal of haematology. 1989 Jun 19. |
PMID: 2713269 |
Expression of a multidrug resistance gene in blast crisis of chronic myelogenous leukemia. |
Pirker R, Goldstein LJ, Ludwig H, Linkesch W, Lechner C, Gottesman MM, Pastan I |
Cancer communications. 1990 Aug 23. |
PMID: 2639725 |
142 Einträge | 1, 2, 3, 4, 5, 6, 7, 8 › » |
Seite 1 / 8
![]() |